- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00355121
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine.
The main objectives are:
Immunogenicity:
To evaluate the antibody responses to both vaccines when Menactra vaccine is given concomitantly with DAPTACEL® compared to when either vaccine is given alone.
Safety:
To evaluate the rate of local and systemic reactions when DAPTACEL® and Menactra vaccines are administered concomitantly compared to when each vaccine is given alone.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72205
-
-
Colorado
-
Boulder, Colorado, États-Unis, 80304
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
-
Layton, UT 84041, Georgia, États-Unis, 30062
-
-
Kentucky
-
Bardstown, Kentucky, États-Unis, 40004
-
-
Massachusetts
-
Woburn, Massachusetts, États-Unis, 01801
-
-
Missouri
-
Bridgeton, Missouri, États-Unis, 63044
-
St. Louis, Missouri, États-Unis, 63141
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87108
-
-
New York
-
Rochester, New York, États-Unis, 14620
-
Syracuse, New York, États-Unis, 13210
-
-
Ohio
-
Akron, Ohio, États-Unis, 44308
-
Cincinnati, Ohio, États-Unis, 45229
-
Columbus, Ohio, États-Unis, 43205
-
University Heights, Ohio, États-Unis, 44118
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15241
-
Sellersville, Pennsylvania, États-Unis, 18960
-
-
Tennessee
-
Kingsport, Tennessee, États-Unis, 37660
-
-
Utah
-
Layton, Utah, États-Unis, 84041
-
Ogden, Utah, États-Unis, 84405
-
Pleasant Grove, Utah, États-Unis, 84062
-
Provo, Utah, États-Unis, 84604
-
Salt Lake City, Utah, États-Unis, 84123
-
South Jordan, Utah, États-Unis, 84095
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23510
-
-
Washington
-
Spokane, Washington, États-Unis, 99220
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy, as determined by medical history and physical examination.
- Aged 4 to < 7 years at the time of study vaccination on Day 0.
- Informed consent form that has been approved by the Institutional Review Board (IRB) and signed/dated by the parent or legal guardian.
- Previous documented vaccination history of 4th dose diphtheria, tetanus and acellular pertussis (DTaP) series.
Exclusion Criteria:
- Serious chronic disease (e.g. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, hematologic)
- Known or suspected impairment of immunologic function
- Acute medical illness with or without fever within the last 72 hours or temperature ≥ 100.4°F (≥ 38°C) at the time of enrollment
- History of documented invasive meningococcal disease or previous meningococcal vaccination
- Received a 5th dose vaccination with any tetanus, diphtheria or pertussis vaccine, or 4th dose of IPV prior to this study.
- Received either immune globulin or other blood products within the last 3 months; or received injected or oral corticosteroids, or other immunomodulator therapy, within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting < 7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment.
- Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw.
- Suspected or known hypersensitivity to any of the study vaccine components, history of serious or life-threatening reaction to the trial vaccines or a vaccine containing the same substances.
- Thrombocytopenia or a bleeding disorder contraindicating IM vaccination.
- Unavailable for the entire study period, or unable to attend the scheduled visits or to comply with the study procedures.
- Enrolled in another clinical trial.
- Diagnosed with any condition, which, in the opinion of the physician investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
- Received any other vaccine 30 days prior to the first study vaccination or scheduled to receive any vaccination during the course of the study.
- Personal or family history of Guillain-Barré Syndrome (GBS).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group 1
DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
|
0.5 mL IM of each vaccine.
(DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
Autres noms:
0.5 mL, IM of each vaccine.
(DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
Autres noms:
0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
Autres noms:
|
|
Expérimental: Group 2
DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
|
0.5 mL IM of each vaccine.
(DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
Autres noms:
0.5 mL, IM of each vaccine.
(DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
Autres noms:
0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
Autres noms:
|
|
Expérimental: Group 3
Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
|
0.5 mL IM of each vaccine.
(DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
Autres noms:
0.5 mL, IM of each vaccine.
(DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
Autres noms:
0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Antibodies Against Diphtheria and Tetanus at ≥ 1.0 IU/mL After DAPTACEL Vaccination
Délai: Day 30 post-vaccination (Visit 1)
|
Serum antibody titers were assessed for diphtheria by a seroneutralization assay and for tetanus by enzyme linked immunosorbent assay.
|
Day 30 post-vaccination (Visit 1)
|
|
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W-135 After Menactra Vaccination at Visit 1.
Délai: Day 30 post-vaccination (Visit 1)
|
Serum antibody titers against meningococcal serogroups A, C, Y, and W-135 were assessed by serum bactericidal assay using human complement (SBA HC)
|
Day 30 post-vaccination (Visit 1)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Geometric Mean Concentrations (GMCs) of Antibodies Against the Pertussis Antigens After DAPTACEL Vaccination at Visit 1
Délai: Day 30 post-vaccination 1
|
Serum antibody titers against pertussis were assessed for pertussis toxoid (PT), filamentous hemagglutinin (FHA), Fimbriae types 2 and 3 (FIM), and pertactin (RN) by enzyme linked immunosorbent assay (ELISA).
|
Day 30 post-vaccination 1
|
|
Serum Bactericidal Assay Using Human Complement Geometric Mean Titers for Serogroups A, C, Y, and W-135 After Menactra Vaccination
Délai: Day 30 post-vaccination
|
Serum antibody titers against meningococcal serogroups A, C, Y, and W-135 were assessed by serum bactericidal assay using human complement (SBA HC)
|
Day 30 post-vaccination
|
|
Number of Participants Reporting Fever When DAPTACEL and Menactra Vaccines Were Administered Concomitantly and Those Reporting When DAPTACEL Was Administered With IPOL Vaccine
Délai: Day 0 through Day 7 post-vaccination at Visit 1
|
Fever was defined as a maximum oral temperature of ≥ 100.4ºF.
|
Day 0 through Day 7 post-vaccination at Visit 1
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Geometric Mean Titers Against Poliovirus After IPOL Vaccination.
Délai: Day 30 post-vaccination
|
Serum antibodies were assessed for poliovirus types 1, 2, and 3 by serum neutralization assay.
|
Day 30 post-vaccination
|
|
Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccinations at Visit 1
Délai: Day 0 through Day 7 post-vaccination
|
Solicited Injection Site Reactions: Pain, Erythema, and Redness.
Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
|
Day 0 through Day 7 post-vaccination
|
|
Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination at Visit 2
Délai: Day 0 through Day 7 post-vaccination
|
Solicited Injection Site Reactions: Pain, Erythema, and Redness.
Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
|
Day 0 through Day 7 post-vaccination
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies métaboliques
- Maladies du système nerveux central
- Maladies du système nerveux
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Manifestations neurologiques
- Maladies neuromusculaires
- Infections du système nerveux central
- Infections à Bordetella
- Infections bactériennes à Gram négatif
- Infections bactériennes
- Infections bactériennes et mycoses
- Infections bactériennes à Gram positif
- Manifestations neuromusculaires
- Infections à Actinomycétales
- Infections à entérovirus
- Infections à Picornaviridae
- Maladies de la moelle épinière
- Infections à Clostridium
- Hypocalcémie
- Troubles du métabolisme calcique
- Infections à corynébactéries
- Méningite bactérienne
- Infections bactériennes du système nerveux central
- Infections méningococciques
- Infections à Neisseriacées
- Myélite
- Coqueluche
- Tétanos
- Diphtérie
- Tétanie
- Méningite, méningocoque
- Méningite
- Poliomyélite
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Vaccins
Autres numéros d'identification d'étude
- MTA43
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .